Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO1996040295) MONOCLONAL ANTIBODY FRAGMENT TO HUMAN OVARIAN CANCERS
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/1996/040295 International Application No.: PCT/US1996/009819
Publication Date: 19.12.1996 International Filing Date: 07.06.1996
Chapter 2 Demand Filed: 07.01.1997
IPC:
A61K 38/00 (2006.01) ,A61K 51/10 (2006.01) ,C07K 16/30 (2006.01) ,G01N 33/574 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
51
Preparations containing radioactive substances for use in therapy or testing in vivo
02
characterised by the carrier
04
Organic compounds
08
Peptides, e.g. proteins
10
Antibodies or immunoglobulins; Fragments thereof
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
28
against receptors, cell surface antigens or cell surface determinants
30
from tumour cells
G PHYSICS
01
MEASURING; TESTING
N
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33
Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48
Biological material, e.g. blood, urine; Haemocytometers
50
Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53
Immunoassay; Biospecific binding assay; Materials therefor
574
for cancer
Applicants:
SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH [US/US]; 1275 York Avenue New York, NY 10021, US (AllExceptUS)
LLOYD, Kenneth, O. [US/US]; US (UsOnly)
FEDERICI, Mark, G. [US/US]; US (UsOnly)
DIVGI, Chaitanya, R. [IN/US]; US (UsOnly)
KOSTAKOGLU, Lale [TR/TR]; TR (UsOnly)
Inventors:
LLOYD, Kenneth, O.; US
FEDERICI, Mark, G.; US
DIVGI, Chaitanya, R.; US
KOSTAKOGLU, Lale; TR
Agent:
WHITE, John, P.; Cooper & Dunham L.L.P. 1185 Avenue of the Americas New York, NY 10036, US
Priority Data:
08/478,19007.06.1995US
Title (EN) MONOCLONAL ANTIBODY FRAGMENT TO HUMAN OVARIAN CANCERS
(FR) FRAGMENT D'ANTICORPS MONOCLONAL DIRIGE CONTRE DES CANCERS DE L'OVAIRE CHEZ LA FEMME
Abstract:
(EN) The biodistribution and pharmacokinetics of intact and F(ab')2 fragments of radiolabeled (125I) monoclonal antibody (Mab) MX-35 and a control mAB were compared in nude mice bearing xenografts of OVCAR-3 human epithelial ovarian cancer. The highest tumor to blood ratio was 12.8 for the F(ab')2 fragment and 1.9 for intact Mab MX-35. Maximum tumor to normal tissue ratios were 64 for fragment and 12.3 for intact antibody. The maximum percent injected dose per gm (%IDg-1) of Mab in tumor was 10.4 % for F(ab')2 fragments and 1.6 % for intact antibody when administered intravenously and 8.2 % for F(ab')2 fragments and 2.3 % for intact MX-35 when injected intraperitoneally. The finding of higher percentage ID g-1 for the fragments is unexpected and is in contrast to other published studies.
(FR) On a comparé la biodistribution et la pharmacocinétique de fragments intacts et de F(ab')2 d'anticorps monoclonal (Mab) MX-35 radiomarqué (125I) et d'un mAB de contrôle chez des souris nudes porteuses d'hétérogreffes de cancer d'ovaire épithélial de la femme OVCAR-3. Le rapport le plus élevé entre la tumeur et le sang était de 12,8 pour le fragment de F(ab')2 et de 1,9 pour le Mab MX-35 intact. Les rapports maximum entre la tumeur et le tissu normal étaient de 64 pour le fragment et de 12,3 pour l'anticorps intact. Le pourcentage maximum de dose injectée par gm (%ID g -1) de Mab dans la tumeur était de 10,4 % pour les fragments de F(ab')2 et de 1,6 % pour l'anticorps intact, administré par voie intraveineuse, de 8,2 % pour les fragments de F(ab')2 et de 2,3 % pour MX-35 intact, injecté par voie intrapéritonéale. La découverte d'un pourcentage d'ID g -1 plus important pour les fragments est inattendue et contraste avec d'autres études publiées.
Designated States: AU, CA, IL, JP, MX, US
European Patent Office (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
Publication Language: English (EN)
Filing Language: English (EN)